Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × avelumab × CNS × Clear all

Phase

Phase 1 6 Phase 2 2 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 13 Genitourinary 10 Gastrointestinal 10 Dermatologic 8 Breast 6 Head & Neck 5 Gynecologic 5 Tumor-Agnostic 4 Sarcoma 4 Other hematologic neoplasm 4 Other solid neoplasm 2 Endocrine 2 NET 1 Lymphoid 1 CNS 1

Conditions

Interventions

Temozolomide 94 Radiotherapy 43 Bevacizumab 29 Carboplatin 22 Irinotecan 18 Radiosurgery 16 pembrolizumab 15 Radiation 14 Nivolumab 14 Magnetic Resonance Spectroscopy 9 Cyclophosphamide 9 Trastuzumab 8 Surgical Procedures, Operative 7 Radiotherapy, Intensity-Modulated 7 Pemetrexed 7 Paclitaxel 7 Interleukin-2 7 Filgrastim 7 Erlotinib Hydrochloride 7 Carmustine 7 fludarabine 6 Specimen Handling 6 Ipilimumab 6 Granulocyte-Macrophage Colony-Stimulating Factor 6 Everolimus 6 Capecitabine 6 aldesleukin 5 Vorinostat 5 Radiotherapy, Conformal 5 Melphalan 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03750071 2022-10-20

VXM01 Plus Avelumab Combination Study in Progressive Glioblastoma

Vaximm GmbH

Phase 1/2 Unknown

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡